Vizsgálati helyszín
Ege Universitesi Hastanesi
Izmir, 35100, TörökországMég nincs intézményhez kötve
- 16futó vizsgálat
- 3lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 19 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis15 vizsgálat
- 2. fázis3 vizsgálat
- 1. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz8 vizsgálat
- Toboroz7 vizsgálat
- Lezárult3 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Eli Lilly and Company9 vizsgálat
- Pfizer6 vizsgálat
- Gilead Sciences2 vizsgálat
- Loxo Oncology, Inc.1 vizsgálat
- Mirati Therapeutics Inc.1 vizsgálat
Futó vizsgálatok
Toboroz
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· 3. fázis· Eli Lilly and Company· Forrás
Contact: Burcu Cakar (principal investigator)
Toboroz
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· 3. fázis· Pfizer· Forrás
Toboroz
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086· 3. fázis· Eli Lilly and Company· Forrás
Contact: Nalan Unal (principal investigator)
Toboroz
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099· 3. fázis· Eli Lilly and Company· Forrás
Contact: Nalan Unal (principal investigator)
Toboroz
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310· 3. fázis· Mirati Therapeutics Inc.· Forrás
Contact: Pinar Gursoy, Site 0200
Fut, nem toboroz
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· 3. fázis· Pfizer· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478· 2. fázis· Loxo Oncology, Inc.· Forrás
Contact: Güray Saydam (principal investigator)
Fut, nem toboroz
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943· 2. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· 3. fázis· Eli Lilly and Company· Forrás
Contact: Tuncay Goksel (principal investigator)
Toboroz
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
NCT05568719· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
NCT02779751· 1. fázis· Eli Lilly and Company· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek